DCF Advisers LLC Purchases New Position in LENSAR, Inc. $LNSR

DCF Advisers LLC purchased a new position in LENSAR, Inc. (NASDAQ:LNSR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 118,217 shares of the company’s stock, valued at approximately $675,000. DCF Advisers LLC owned 0.96% of LENSAR at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of LNSR. Credit Industriel ET Commercial increased its position in shares of LENSAR by 0.8% in the fourth quarter. Credit Industriel ET Commercial now owns 124,483 shares of the company’s stock valued at $1,448,000 after buying an additional 1,000 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of LENSAR by 129.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after buying an additional 1,131 shares in the last quarter. JPMorgan Chase & Co. grew its stake in LENSAR by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after acquiring an additional 1,254 shares during the period. Barclays PLC grew its stake in LENSAR by 10.3% in the 4th quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after acquiring an additional 1,389 shares during the period. Finally, Vanguard Group Inc. grew its stake in LENSAR by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after acquiring an additional 1,446 shares during the period. Hedge funds and other institutional investors own 40.15% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LNSR. Wall Street Zen upgraded shares of LENSAR from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. BTIG Research lifted their target price on shares of LENSAR from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Lake Street Capital reissued a “buy” rating and set a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of LENSAR in a research report on Friday, August 7th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, LENSAR presently has an average rating of “Hold” and an average target price of $11.00.

LENSAR Price Performance

Shares of NASDAQ:LNSR opened at $8.72 on Thursday. The business’s 50 day moving average price is $6.05 and its 200-day moving average price is $7.25. The firm has a market capitalization of $107.17 million, a PE ratio of -26.42 and a beta of 0.89. LENSAR, Inc. has a 1 year low of $4.95 and a 1 year high of $12.96.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. LENSAR had a negative return on equity of 529.08% and a net margin of 57.57%.The firm had revenue of $16.50 million during the quarter, compared to analysts’ expectations of $14.65 million.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.